by The extracellular matrix (ECM) market includes a wide range of biomaterials used primarily in tissue engineering for wound healing and regenerative medicine. ECM biomaterials mimic the properties of natural extracellular matrices in supporting cell migration, differentiation, and tissue organization, playing a crucial role in wound healing, tissue regeneration, and the repair of damaged cells, organs, and tissues. The increasing prevalence of chronic wounds worldwide due to rising incidence of diabetes, pressure ulcers, and surgical wounds has driven the demand for advanced ECM biomaterials. The lack of availability of organ donors has also boosted research on developing tissues and organs from cells and ECM biomaterials to fulfill the global demand.
The global extracellular matrix market is estimated to be valued at US$ 46.12 Bn in 2023 and is expected to exhibit a CAGR of 5.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The key trend gaining traction in the extracellular matrix market includes the increased adoption of decellularized ECM biomaterials. Decellularization is a process of removing cellular components from tissues and organs while retaining the ultrastructure, proteins, and glycoproteins of the ECM. Decellularized tissues mimic the biochemical and biomechanical properties of native tissues more closely as compared to traditional collagen-based biomaterials. Successful clinical applications of decellularized ECM products such as dermis, small intestine submucosa, and urinary bladder matrix have increased their use in wound healing, hernia repair, and soft tissue reconstruction. Other decellularized tissues under research include liver, lung, heart and blood vessels. Advancements in decellularization techniques focusing on maintaining ECM composition, architecture, and function are expected to boost the adoption of these third-generation biomimetic matrices over the forecast period.
Porter’s Analysis
Threat of new entrants: The high capital requirements and economies of scale of the extracellular matrix market create barriers to entry for new competitors.
Bargaining power of buyers: The existence of many players in the market allows buyers to compare prices and exert pressure on prices.
Bargaining power of suppliers: Suppliers of raw materials have some bargaining power given the specialized nature of materials required.
Threat of new substitutes: Some procedures such as stem cell therapy could emerge as substitutes in the future but currently there are limited close substitutes.
Competitive rivalry: The extracellular matrix market features many mid-sized players competing on product differentiation and innovation.
Key Takeaways
The global extracellular matrix market size is expected to witness high growth. Regional analysis related content comprises growth is forecast to be fastest in North America and Asia Pacific. Rising demand for advanced wound care treatments and regenerative surgical procedures is driving the market in these regions.
Key players operating in the extracellular matrix market are VISUfarma, Johnson & Johnson, Otsuka Holdings Co. Ltd., OASIS Medical, Novartis AG, Sentiss Pharma Pvt. Ltd., AbbVie Inc. (Allergan PLC), Bausch Health Companies Inc., Santen Pharmaceutical Co. Ltd., and Sun Pharmaceutical Industries Ltd., among others. These players are focusing on new product launches and expansion in emerging markets through collaborations.
The global extracellular matrix market size for 2023 is US$ 46.12 Bn. Regional analysis related content comprises North America currently dominates the market due to advanced healthcare infrastructure and increasing adoption of innovative treatments. Asia Pacific is expected to witness high growth during the forecast period attributable to growing medical tourism, rising healthcare spending by countries.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
